[go: up one dir, main page]

PE20240217A1 - Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 - Google Patents

Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Info

Publication number
PE20240217A1
PE20240217A1 PE2023001362A PE2023001362A PE20240217A1 PE 20240217 A1 PE20240217 A1 PE 20240217A1 PE 2023001362 A PE2023001362 A PE 2023001362A PE 2023001362 A PE2023001362 A PE 2023001362A PE 20240217 A1 PE20240217 A1 PE 20240217A1
Authority
PE
Peru
Prior art keywords
acyltransferase
inhibitors
preparation
compounds
heteroatoms
Prior art date
Application number
PE2023001362A
Other languages
English (en)
Inventor
Yeon-Hee Lim
Jianming Bao
James P Roane
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of PE20240217A1 publication Critical patent/PE20240217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de oxindol de formula I, una sal farmaceuticamente aceptable del mismo, en donde: X, Y y Z se seleccionan independientemente entre N o C(R5); R1 es fenilo sin sustituir o sustituido con 1-3 R6, o heteroarilo de 5 o 6 miembros que contiene 1-4 heteroatomos, entre otros; R2a y R2b se seleccionan independientemente entre H, halogeno, hidroxi, alquilo (C1-6), entre otros; R3 es heterociclilo de 4 a 7 miembros que contiene 1-3 heteroatomos seleccionados de N, O y S, heteroarilo de 5 o 6 miembros que contiene 1, 2 o 3 heteroatomos seleccionados de N, O y S, entre otros; R4 es H, alquilo (C1-3), o R3 y R4 se combinan junto con el atomo de nitrogeno al que estan unidos para formar un anillo heterociclilo mono- o biciclico que contiene 1 o 2 heteroatomos seleccionados de N, O y S, en donde el anillo heterociclilo esta sin sustituir o sustituido con 1-3 R11. Un compuesto seleccionado es 1-(3-(difluorometoxi)fenil)-3,3-dimetil-N-(3-metil-1,1-dioxidotietan-3-il)-2- oxoindolin-5-carboxamida. Dichos compuestos son inhibidores de diacilglicerol O-aciltransferasa 2 (DGAT2). Tambien se refiere a un metodo de preparacion de dichos compuestos, y a una composicion farmaceuticamente que los comprende, siendo utiles para prevenir, tratar o actuar como un agente de reversion para la esteatosis hepatica, esteatohepatitis no alcoholica (EHNA), entre otros.
PE2023001362A 2020-10-08 2021-10-06 Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 PE20240217A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089063P 2020-10-08 2020-10-08
PCT/US2021/053681 WO2022076496A1 (en) 2020-10-08 2021-10-06 Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Publications (1)

Publication Number Publication Date
PE20240217A1 true PE20240217A1 (es) 2024-02-16

Family

ID=78709520

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001362A PE20240217A1 (es) 2020-10-08 2021-10-06 Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Country Status (19)

Country Link
US (2) US12410159B2 (es)
EP (1) EP4225735A1 (es)
JP (1) JP7482324B2 (es)
KR (1) KR20230079427A (es)
CN (1) CN116457346A (es)
AR (1) AR123701A1 (es)
AU (1) AU2021358946A1 (es)
CA (1) CA3195032A1 (es)
CL (1) CL2023000978A1 (es)
CO (1) CO2023004366A2 (es)
CR (1) CR20230160A (es)
DO (1) DOP2023000068A (es)
EC (1) ECSP23034049A (es)
IL (1) IL301799A (es)
MX (1) MX2023003844A (es)
PE (1) PE20240217A1 (es)
TW (1) TW202229232A (es)
WO (1) WO2022076496A1 (es)
ZA (1) ZA202304150B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023279857A1 (en) * 2022-06-03 2024-11-14 Domain Therapeutics Novel par-2 inhibitors
AR131250A1 (es) 2022-12-02 2025-02-26 Merck Sharp & Dohme Llc Preparación de derivados condensados de azol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6691498A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6489476B1 (en) 1998-09-09 2002-12-03 Metabasis Therapeutics, Inc. Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
WO2003053363A2 (en) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
CN100457730C (zh) 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
WO2009001836A1 (en) 2007-06-28 2008-12-31 Semiconductor Energy Laboratory Co., Ltd. Manufacturing method of semiconductor device
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
US8124766B2 (en) * 2008-12-03 2012-02-28 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase
WO2010077839A1 (en) * 2008-12-15 2010-07-08 Wyeth Llc (Formerly Known As Wyeth) Substituted oxindol cb2 agonists for pain treatment
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
BR112016012011B8 (pt) 2013-11-26 2021-12-14 Hewlett Packard Development Co Cabeçote de impressão de ejeção de fluido, aparelho de ejeção de fluido e método
CR20160405A (es) 2014-03-17 2016-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2016036636A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036638A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AU2016294347B2 (en) 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CA3043206A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
MA46856A (fr) * 2016-11-18 2019-09-25 Merck Sharp & Dohme Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.
US11541039B2 (en) 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium
CA3194700A1 (en) 2020-10-08 2022-04-14 Leukos Biotech, S. L. Potent and selctive compounds as serotonin 1b receptor modulators

Also Published As

Publication number Publication date
KR20230079427A (ko) 2023-06-07
US12410159B2 (en) 2025-09-09
CA3195032A1 (en) 2022-04-14
AU2021358946A1 (en) 2023-06-08
JP2023541714A (ja) 2023-10-03
ECSP23034049A (es) 2023-06-30
CL2023000978A1 (es) 2023-09-29
MX2023003844A (es) 2023-04-14
AR123701A1 (es) 2023-01-04
DOP2023000068A (es) 2023-05-31
AU2021358946A9 (en) 2024-02-08
US20220112181A1 (en) 2022-04-14
CO2023004366A2 (es) 2023-04-27
WO2022076496A1 (en) 2022-04-14
TW202229232A (zh) 2022-08-01
CN116457346A (zh) 2023-07-18
US20240327391A1 (en) 2024-10-03
US12428411B2 (en) 2025-09-30
ZA202304150B (en) 2024-12-18
JP7482324B2 (ja) 2024-05-13
CR20230160A (es) 2023-06-02
EP4225735A1 (en) 2023-08-16
IL301799A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20240765A1 (es) Compuestos para la inhibicion de nlrp3 y usos de estos
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
PH12021550400A1 (en) Cardiac sarcomere inhibitors
UY38057A (es) Inhibidores de sarcómero cardíaco
CR20230529A (es) Inhibidores de nlrp3
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
EA200600258A1 (ru) Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
EA200801828A3 (ru) Соединения 1,2,4,5- тетрагидро-3н-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
AR118247A1 (es) Combinación de compuestos activos
PE20240217A1 (es) Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
PE20252677A1 (es) Amidas de azolipiridina piridazinona como inhibidores de sos1
AR122092A1 (es) Inhibidores de diacilglicerol o-aciltransferasa 2
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
PE20251706A1 (es) Compuestos de urea triciclica como inhibidores de v617f de jak2
PE20220376A1 (es) Compuestos triciclicos y su uso